The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
RAC2 GTPase Deficiency and Myeloid Cell Dysfunction in Human and Mouse
Abstract
Rho GTPases including Rho, Rac, and Cdc42 act as intracellular molecular switches to control cellular responses such as actin cytoskeleton rearrangement, gene transcription, cell growth, and possibly transformation. Their roles have been increasingly implicated in activation of signaling processes in leukocytes including integrin-mediated signal transduction and growth factor-induced cell survival and proliferation pathways. In particular, functional disruption of Rac2, a hematopoietic-specific Rho GTPase, causes severe myeloid cell dysfunction in both mouse and man. Rac2-deficient mice and a human patient with a D57N Rac2 mutant share a phenotype of leukocytosis with defective neutrophil chemotaxis and superoxide production in response to some, but not all, agonists. Our studies also suggested that the phenotypic abnormalities associated with D57N may involve not only neutrophil cellular functions, but also abnormal cell survival in other hematopoietic cells. Together, these data demonstrate a critical and unique role for Rac2 in normal neutrophil function and define a new genetic immunodeficiency syndrome in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the genetic knock-out of Rac2 and later the conditional knock-out of Rac1 allowed us and others to demonstrate that in phagocytic cells Rac1 and Rac2 are differentially required for both chemotaxis and generation of phagocytic oxidants needed for bacterial killing56,60,24.”
From Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders (2013) · cites this paper as [60]
In the citing paper
“Studies in mouse Rac2 2/2 neutrophils have demonstrated different effector proteins involved in O 2 • 2 production (p67 phox ) and cell migration (Pak1), indicating that multiple pathways are affected by the loss of Rac2 in these cells.26,33,34”
From Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects (2019) · cites this paper as [33]
Citations
Cites
Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization
Yang, F.-C., Atkinson, S. J., Gu, Y., Borneo, J. B., Roberts, A. W., Zheng, Y., Pennington, J., & Williams, D. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101546898 · Cited by 201
Self-citation
Research works printed but not linked: 35
- Arnaout, 1984, J Clin Invest, 74, 1291, 10.1172/JCI111539 · DOI
- Roos, 1996, Blood, 87, 1663, 10.1182/blood.V87.5.1663.1663 · DOI
- Boxer, 1974, N Engl J Med, 291, 1093, 10.1056/NEJM197411212912101 · DOI
- Lowe, 1997, J Clin Invest, 99, 822, 10.1172/JCI119244 · DOI
- Knaus, 1991, Science, 254, 1512, 10.1126/science.1660188 · DOI · Paper page
- MacKay, 1998, J Biol Chem, 273, 20685, 10.1074/jbc.273.33.20685 · DOI
- Allen, 1997, J Cell Sci, 110, 707, 10.1242/jcs.110.6.707 · DOI
- Bengtsson, 1990, Proc Natl Acad Sci USA, 87, 2921, 10.1073/pnas.87.8.2921 · DOI
- Cox, 1997, J Exp Med, 186, 1487, 10.1084/jem.186.9.1487 · DOI · Paper page
- Narumiya, 1997, FEBS Lett, 410, 68, 10.1016/S0014-5793(97)00317-7 · DOI
- Van Aelst, 1997, Genes Dev, 11, 2295, 10.1101/gad.11.18.2295 · DOI
- Hall, 1998, Science, 279, 509, 10.1126/science.279.5350.509 · DOI
- Didsbury, 1989, J Biol Chem, 264, 16378, 10.1016/S0021-9258(19)84716-6 · DOI · Paper page
- Shirsat, 1990, Oncogene, 5, 769
- Moll, 1991, Oncogene, 6, 863
- Haataja, 1997, J Biol Chem, 272, 20384, 10.1074/jbc.272.33.20384 · DOI · Paper page
- Segal, 1993, Trends Biochem Sci, 18, 43, 10.1016/0968-0004(93)90051-N · DOI · Paper page
- Abo, 1991, Nature, 353, 668, 10.1038/353668a0 · DOI
- Abo, 1992, J Biol Chem, 267, 16767, 10.1016/S0021-9258(18)41846-7 · DOI
- Roberts, 1999, Immunity, 10, 183, 10.1016/S1074-7613(00)80019-9 · DOI · Paper page
- Yang, 2000, Immunity, 12, 557, 10.1016/S1074-7613(00)80207-1 · DOI · Paper page
- Li, 2000, Science, 288, 2219, 10.1126/science.288.5474.2219 · DOI · Paper page
- Maly, 1996, Cell, 86, 643, 10.1016/S0092-8674(00)80137-3 · DOI · Paper page
- Mayadas, 1993, Cell, 74, 541, 10.1016/0092-8674(93)80055-J · DOI
- Wilson, 1993, J Immunol, 151, 1571, 10.4049/jimmunol.151.3.1571 · DOI
- Cacalano, 1994, Science, 265, 682, 10.1126/science.8036519 · DOI
- Witke, 1995, Cell, 81, 41, 10.1016/0092-8674(95)90369-0 · DOI
- Diekmann, 1995, Embo J, 14, 5297, 10.1002/j.1460-2075.1995.tb00214.x · DOI · Paper page
- Kim, 2001, J Immunol, 166, 1223, 10.4049/jimmunol.166.2.1223 · DOI · Paper page
- Ambruso, 2000, PNAS, 97, 4654, 10.1073/pnas.080074897 · DOI · Paper page
- Williams, 2000, Blood, 96, 1646
- Pai, 1989, Nature, 341, 209, 10.1038/341209a0 · DOI
- Bourne, 1991, Nature, 349, 117, 10.1038/349117a0 · DOI · Paper page
- Gu, 2001, J Biol Chem, 276, 15929, 10.1074/jbc.M010445200 · DOI · Paper page
- Roos, 1993, Blood, 81, 2735, 10.1182/blood.V81.10.2735.2735 · DOI
Cited by
RHO GTPases: from new partners to complex immune syndromes
El Masri, R., & Delon, J. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00500-7 · Cited by 131
Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects
Hsu, A. P., Donkó, A., Arrington, M. E., Swamydas, M., Fink, D., Das, A., Escobedo, O., Bonagura, V., Szabolcs, P., Steinberg, H. N., et al. (2019) · Blood · doi:10.1182/blood-2018-11-886028 · Cited by 92
Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders
Troeger, A., & Williams, D. A. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.07.002 · Cited by 73
Self-citationDavis, J. M., Huang, M., Botts, M. R., Hull, C. M., & Huttenlocher, A. (2016) · Infection and Immunity · doi:10.1128/iai.00506-16 · Cited by 62
Metadata
- Authors
- Gu, Y., & Williams, D. A.
- Venue
- Journal of Pediatric Hematology/Oncology
- Published
- 2002-12
- Volume
- 24
- Issue
- 9
- Pages
- 791-794
- ISSN
- 1077-4114
- Cited by
- 25
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAC2 GTPase Deficiency and Myeloid Cell Dysfunction in Human and Mouse. https://app.cochat.ai/papers/10.1097/00043426-200212000-00027
- The paper
- Gu, Y., & Williams, D. A. (2002). RAC2 GTPase Deficiency and Myeloid Cell Dysfunction in Human and Mouse. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/00043426-200212000-00027